News and Trends 29 Aug 2019 HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs The French biotech HiFiBiO has raised €60M in a Series C round to finance the development of antibody drugs for cancer and autoimmune diseases based on its single-cell screening technology. HiFiBiO will use the money to accelerate the progress of its drugs to clinical trials, though it has not specified when it plans to begin […] August 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jul 2019 Belgian Biotech Raises €35M to Develop Eco-Friendly Pesticides The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired by llama antibodies. AgroSavfe will use the funds to develop and manufacture its lead protein fungicide on a commercial scale. The company aims to get approval from the US Environmental Protection Agency and launch the […] July 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2019 Janssen and Genmab Team Up Again for Another Potential Cancer Blockbuster Janssen and the Danish biotech Genmab will collaborate to develop a new antibody that could outperform their blockbuster cancer drug Darzalex in certain types of blood cancer. Genmab will develop the antibody treatment until it completes clinical proof-of-concept studies in the blood cancers multiple myeloma and diffuse large B-cell lymphoma. At that point, Janssen will […] June 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2019 Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II The German company InflaRx has seen its shares on the Nasdaq plummet after announcing that its treatment for an inflammatory skin disease failed to beat the placebo in a phase IIb trial. The trial had enrolled 179 patients with hidradenitis suppurativa, an incurable condition causing painful lumps on the skin. By the 16th week of […] June 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 31 May 2019 This Biotech Treats a Neurological Autoimmune Disorder Using DNA We’re jumping into Poland this week. Pure Biologics is a biotech based in Wrocław developing DNA molecules that could treat the incurable neurological condition Devic’s disease with fewer side effects than existing treatments. Mission: To develop a treatment that makes an existing treatment for Devic’s disease, plasmapheresis, more targeted and with fewer side effects than […] May 31, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2019 Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of […] January 28, 2019 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2019 Sanofi Obtains License for French Company’s Antibody Engineering Platform Sanofi has signed a licensing deal with French biotech Biomunex, whose antibody technology has the potential to develop new immunotherapy treatments for cancer and infectious diseases. Sanofi will give Biomunex an upfront payment, along with further installments upon achieving key development milestones. The amounts have not been disclosed. Biomunex is able to make a wide variety […] January 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Dec 2018 Looking Back on 2018: Our 10 Most Popular Interviews As 2018 draws to a close and our thoughts are torn between holiday plans and what the new year may bring, we decided to look back and revisit the people and the stories that attracted our readers the most during the year. These were well received the first time around, so we thought you might […] December 24, 2018 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2018 Antibody Hitting Tumor Self-Destruct Button Passes Phase I A first-in-class antibody cancer treatment, from the French company Netris Pharma, has shown good safety and anti-tumor effects in a phase I trial in patients with advanced solid tumors. The antibody met the trial’s primary objective of good tolerability in the 19 recruited patients. In addition, the antibody helped to stabilize the disease and shrink […] December 12, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Nov 2018 Berlin Biotech Raises €24M to Progress Septic Shock Candidate to Clinic Adrenomed closed a €24M Series D round to fund further development of its antibody drug that treats septic shock by preventing excessive fluid loss and preserving the blood vessel walls. Wellington Partners and HBM Healthcare Investments, who specialize in investing in life science companies, joined existing shareholders to lead the fundraising round. Sepsis and resulting […] November 27, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 23 Nov 2018 This Biotech Arms Tumor-Busting Cells to Treat Cancer In the medieval city of ‘s-Hertogenbosch, the Netherlands, Lava Therapeutics is developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells. Mission: Develop antibodies that recruit innate immune cells near tumors and activate them to kill cancer cells. T cells are immune cells that have a strong potential […] November 23, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2018 Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a Phase III trial. The blockbuster antibody daratumumab, developed by Janssen using a license from the Danish company Genmab, was given to patients in combination with […] October 31, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email